Controversies in endocrinology - A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 5, 2003, Pages 1927-1932

  Diamanti Kandarakis, Evanthia ^a   Baillargeon, Jean Patrice ^b   Iuorno, Maria J ^c   Jakubowicz, Daniela J ^e   Nestler, John E ^c,d  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e Hospital de Clinicas Caracas   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; METFORMIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; ANTIDIABETIC AGENT;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LEAN BODY WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OLIGOMENORRHEA; ORAL CONTRACEPTION; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ENDOMETRIUM TUMOR; FEMALE;

CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL; DIABETES MELLITUS, TYPE 2; ENDOMETRIAL NEOPLASMS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 0038031022     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021528     Document Type: Review

References (72)

1. Chang RJ, Nakamura RM, Judd HL, Kaplan SA 1983 Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356-359
2. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A 1987 Characterization of groups of hyperandrogenemic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65:499-507
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174
4. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T 1992 Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257-1266
5. Ciaraldi TP, el Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SSC 1992 Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 75:577-583
6. Dunaif A, Xia J, Book CB, Schenker E, Tang Z 1995 Excessive insulto receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96:801-810
7. Jahanfar S, Eden JA, Warren P, Seppälä M, Nguyen TV 1995 A twin study of polycystic ovary syndrome. Fertil Steril 63:478-486
8. Campbell PJ, Gerich JE 1990 Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 70:1114-1118
9. Reaven GM 1988 Banting lecture 1988. Role of insulto resistance in human disease. Diabetes 37:1595-1607
10. Reaven GM 1991 Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care 14:195-202
11. The National Cholesterol Education Program (NCEP) Expert Panel 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). 2001 JAMA 285:2486-2497
12. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141-146
13. Legro RS, Kunselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169
14. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ 2001 Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16:1995-1998
15. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE 2001 Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 286:2421-2426
16. Peppard HR, Marfori J, Iuorno MJ, Nestler JE 2001 Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 24:1050-1052
17. Conn JJ, Jacobs HS, Conway GS 2000 The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 52:81-86
18. Björntorp P 1996 The android woman-a risky condition. J Intern Med 239:105-110
19. Holte J, Gennarelli G, Wide L, Lithell H, Berne C 1998 High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 83:1143-1150
20. Rebuffe-Scrive M, Cullberg G, Lundberg P-A, Lindstedt G, Björntorp P 1989 Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 21:391-397
21. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L 1995 Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15:821-826
22. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA 1998 Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51:415-422
23. Wild RA, Alaupovic P, Parker IJ 1992 Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance. Am J Obstet Gynecol 166:1191-1196
24. Wild RA 1995 Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 98:27S-32S
25. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS 1997 Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108-2116
26. Velazquez EM, Mendoza SG, Wang P, Glueck CJ 1997 Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46:454-457
27. Legro RS, Kunselman AR, Dunaif A 2001 Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111:607-613
28. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I 2001 Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86:4666-4673
29. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N 2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455
30. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD 2001 Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103:1410-1415
31. Lakhani K, Constantinovici N, Purcell WM, Fernando R, Hardiman P 2000 Internal carotid-artery response to 5% carbon dioxide in women with polycystic ovaries. Lancet 356:1166-1167
32. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM 2002 Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87:742-746
33. Mather KJ, Verma S, Corenblum B, Anderson TJ 2000 Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 85:1851-1856
34. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51:581-586
35. Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A 1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:599-604
36. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH 2000 Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20:2414-2421
37. Birdsall MA, Farquhar CM, White HD 1997 Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126:32-35
38. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL 1995 Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:3327-3334
39. Nader S, Riad-Gabriel MG, Saad MF 1997 The effect of a desogestrel-conraining oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 82:3074-3077
40. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO 1998 Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 13:2706-2711
41. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS 2000 Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85:3161-3168
42. Elter K, Imir G, Durmusoglu F 2002 Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 17:1729-1737
43. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS 2003 Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 88:148-156
44. Chasan-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spiegelman D, Manson JE 1997 A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20:330-335
45. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH, Speizer FE 1992 Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia 35:967-972
46. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception 1997 Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 349:1202-1209
47. Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, van der Graaf Y, Rosendaal FR 2001 Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345:1787-1793
48. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L 1989 Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337-343
49. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bogardus C 1993 Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988-1992
50. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR 1990 Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909-915
51. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350
52. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
53. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Azen SP 2001 Protection from type 2 diabetes persists in the TRIPOD cohort eight months after stopping troglitazone. Diabetes 50(Suppl 2):A81 (Abstract)
54. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK 1998 Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 69:691-696
55. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43:647-654
56. Nestler JE, Jakubowicz DJ, Reamer P, Gunn R, Allan G 1999 Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340:1314-1320
57. Iuorno MJ, Jakubowicz DJ, Dillon P, Gunn R, Allan G, Nestler JE 2002 Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 8:417-423
58. UK Prospective Diabetes Study (UKPDS) Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
59. Johnson JA, Majumdar SR, Simpson SH, Toth EL 2002 Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248
60. Coulam CB, Annegers JF, Kranz JS 1983 Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 61:403-407
61. Smyczek-Gargya B, Geppert M 1992 Endometrial cancer associated with polycystic ovaries in young women. Pathol Res Pract 188:946-948
62. Ho SP, Tan KT, Pang MW, Ho TH 1997 Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J 38:11-15
63. Troisi R, Potischman N, Hoover RN, Siiteri P, Brinton LA 1997 Insulin and endometrial cancer. Am J Epidemiol 146:476-482
64. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Persky V, Lurain JR 1996 Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 88:1127-1135
65. Nagamani M, Stuart CA, Dunhardt PA, Doherty MG 1991 Specific binding sites for insulin and insulin-like growth factor I in human endometrial cancer. Am J Obstet Gynecol 165:1865-1871
66. Nagamani M, Stuart CA, Doherty MG 1992 Increased steroid production by the ovarian stromal tissue of postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 74:172-176
67. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM 1997 Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89:1110-1116
68. Vessey MP, Painter R 1995 Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br J Cancer 71:1340-1342
69. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I 1999 Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10:277-284
70. Baillargeon J, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 78 (Abstract OR10-1)
71. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN 2001 Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86:1626-1632
72. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139-146